Results of Operations and Financial Condition. On August 6, 2026, IN8bio, Inc. (the "Company") issued a press release announcing its financial results for the second quarter ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amend…

Termination of a Material Definitive Agreement. As previously disclosed, on November 10, 2022 the Company entered into a Controlled Equity Offering SM Sales Agreement with Cantor Fitzgerald & Co. (“ Cantor ”) as sales agent (the “ Cantor Sales Agreement ”), pursuant to which the Company was permitted to issue and sell, from time to time through Cantor, shares of the Company’s Common Stock. On May 29, 2026, the Company and Cantor mutually agreed to terminate the Cantor Sales Agreement and the…

Entry into a Material Definitive Agreement. On June 1, 2026, IN8bio, Inc. (the “ Company ”) entered into a Capital on Demand TM Sales Agreement (the “ Sales Agreement ”) with JonesTrading Institutional Services LLC (the “ Agent ”) with respect to an at the market offering program under which the Company may issue and sell, from time to time at its sole discretion, shares (the “ Placement Shares ”) of its common stock, par value $0.0001 per share (the “ Common Stock ”), through or to the Agent…

The excerpt is incomplete and does not provide sufficient details to determine the nature of the event.

Results of Operations and Financial Condition. On May 7, 2026, IN8bio, Inc. (the "Company") issued a press release announcing its financial results for the first quarter ended March 31, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended…

Results of Operations and Financial Condition. On March 12, 2026, IN8bio, Inc. (the “Company”) issued a press release announcing its financial results for fourth quarter and fiscal year ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Form 8-K, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of…

Director — Alan S. Roemer: Mr. Roemer resigned as a director and from his roles on the Audit and Compensation Committees.

President — Kate Rochlin: Dr. Kate Rochlin was promoted to President while retaining her role as Chief Operating Officer.

Unregistered Sales of Equity Securities. The information contained in

Entry into a Material Definitive Agreement. Securities Purchase Agreement On December 18, 2025, IN8bio, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with the purchasers named therein (the “Investors”), pursuant to which the Company agreed to issue and sell shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (“Common Stock”), and, in lieu of Common Stock, pre-funded warrants (the “Pre-Funded Warrants” and, together wi…

Results of Operations and Financial Condition. On November 6, 2025, IN8bio, Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Form 8-K, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as…

Results of Operations and Financial Condition. On August 7, 2025, IN8bio, Inc. (the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Form 8-K, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amende…

Material Modification to Rights of Security Holders. (a) On June 3, 2025, IN8bio, Inc. (the “ Company ”) filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to effect a reverse stock split at a ratio of 1-for-30 (the “ Charter Amendment ”). The Charter Amendment was authorized by the stockholders of the Company at the Company’s Annual Meeting of Stockholders held on May 8, 2025. Pursuant to the Charter…

Results of Operations and Financial Condition. On May 7, 2025, IN8bio, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Form 8-K, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (…

Unregistered Sales of Equity Securities. The descriptions of the Transactions, including the description of the Pre-Funded Warrants, in

Entry into a Material Definitive Agreement. Stock Purchase Agreement Amendment and Series B Warrant Amendment On April 27, 2025, IN8bio, Inc. (the “Company”) entered into an Amendment No. 1 (the “SPA Amendment”) to Securities Purchase Agreement, dated September 30, 2024 (the “Purchase Amendment”), to amend the restrictions on certain equity sales by the Company set forth in the Purchase Agreement. In consideration for the SPA Amendment, the Company will enter into amendments with certain hold…

Material Modification to Rights of Security Holders. The descriptions of the Series B Warrant Amendment and Warrant Exercises in

Results of Operations and Financial Condition. On March 13, 2025, IN8bio, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Form 8-K, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Ac…

Director — Travis Whitfill: Mr. Travis Whitfill resigned from the Board and its committees, effective May 9, 2025.

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On February 5, 2025, IN8bio, Inc. (the “Company”) received a notice (the “Extension Notice”) from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) informing the Company that Nasdaq granted the Company an additional 180 calendar days, or until August 4, 2025, to regain compliance with the minimum closing bid price requirement for continued listing on The Nasdaq Capita…

Results of Operations and Financial Condition. On November 12, 2024, IN8bio, Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Form 8-K, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as…

Material Modification Series A Warrant Amendment In connection with the Private Placement, the Company has agreed to amend certain of the Company’s outstanding series A common stock purchase warrants (“Series A Warrants”), representing approximately 11,734,076 shares of the Company’s Common Stock, to (i) reduce the exercise price from $1.25 to $0.45 per share and (ii) extend the termination date of the Series A Warrants to a date that is one year from the Closing Date (collectively, “Amendmen…

Unregistered Sales of Equity Securities. The information contained in

Entry into a Material Definitive Agreement. Securities Purchase Agreement On September 30, 2024, IN8bio, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with the purchasers named therein (the “Investors”), pursuant to which the Company agreed to issue and sell units, comprised of an aggregate of 25,759,595 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (“Common Stock”), 5,646,853 pre-funded warrants (the “Pre-Funde…

Chief Medical Officer — Trishna Goswami, M.D.: Dr. Goswami stepped down as Chief Medical Officer with a severance agreement.